We identified patients with cervical cancer who underwent tumor NGS with the TruSight Oncology 500 panel and collected clinical parameters such as histology, HPV genotyping, tumor markers, and IHC results for PD-L1 and human epidermal growth factor receptor 2 (HER2) receptor status. Here, ERBB2 is linked to cervical cancer.